Statins for Smith-Lemli-Opitz syndrome

To evaluate the efficacy of statin therapy in reducing the frequency or severity of the neurobehavioral abnormalities seen in people with SLOS (e.g. aggression, anxiety, irritability, self-mutilation, autistic behaviors, sleep disturbances, etc.) (Wassif 2017).
To evaluate the potential effects of statin therapy on survival.

This is a protocol.

Health topics:

Genetic disorders > Inborn errors of metabolism > Other

Published:

14 January 2020

Authors:

Ballout RA, Bianconi S, Livinski A, Fu Y, Remaley AT, Porter FD

Primary Review Group:

Cystic Fibrosis and Genetic Disorders Group

See the full Review on

the Cochrane Library

►

Print
PDF
Citation
Ballout RA, Bianconi S, Livinski A, Fu Y, Remaley AT, Porter FD. Statins for Smith-Lemli-Opitz syndrome. Cochrane Database of Systematic Reviews 2020, Issue 1. Art. No.: CD013521. DOI: 10.1002/14651858.CD013521

Don't show again

What role do you identify with the most?

General public, patient, or care giver

Health practitioner

Researcher

Policy Maker

We are collecting information on visitors to our website to ensure Cochrane resources meet the needs of our users. Your data will be anonymised for processing, will be stored securely, and will not be shared with any third parties.